Skip to main content

Nusinersen

Question for Department of Health and Social Care

UIN 130465, tabled on 28 February 2018

To ask the Secretary of State for Health and Social Care, what progress NHS England and Biogenon have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular atrophy.

Answered on

5 March 2018

NHS England has advised that it is continuing discussions with Biogen and the National Institute for Health and Care Excellence about the use of nusinersen (Spinraza) for the treatment of patients with spinal muscular atrophy.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.